l-carnitine and tirzepatide together with tirzepatide l-carnitine 17mg 100mg 1ml

4.73 kcal g 1

Significant weight loss, particularly when it occurs over 12 to 18 months, can result in a reduction in facial fullness, mild skin laxity in the lower face and neck, and changes in facial contour

In TRIUMPH-1, the pivotal Phase 3 general-obesity trial (2,339 participants), the topline results reported on May 21, 2026 showed average weight loss at 80 weeks of 19.0% on 4 mg, 25.9% on 9 mg, and 28.3% (70.3 lbs) on 12 mg, versus 2.2% on placebo

Semaglutide is contraindicated for use in patients with active or a history of pancreatitis, a personal or family history of certain types of thyroid cancer, namely C cell tumors, and multiple endocrine neoplasia syndrome type 2, and hypersensitivity to the medication

Let's dive into what these advancements mean